EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
To focus on providing safer burn treatments for women and armed forces
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
He is a seasoned leader with 34 years of rich and diverse experience across geographies and consumer facing companies such as Xerox India and Bharti Airtel
Subscribe To Our Newsletter & Stay Updated